ebook: How FBDD improves hit rates & delivers high-value targets
Learn how fragment-based drug discovery improves hit rates and delivers higher-value targets using various biophysical methods.
List view / Grid view
Learn how fragment-based drug discovery improves hit rates and delivers higher-value targets using various biophysical methods.
Learn why researchers turned to biophysical methods to expose the molecular mechanisms of neurodegenerative diseases.
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
A study has revealed that a sponge endemic to an Indonesian bay produces manzamine A, a compound which inhibits proteins in cervical cancers.
Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.